Table II.
Characteristics of studies included in the meta-analysis of ulcerative colitis.
| Author (ref) | Mean age | Gender (M/F) | Regimens | Concomitant therapy | Duration | Clinical improvement
|
|
|---|---|---|---|---|---|---|---|
| Antibiotics | Placebo | ||||||
| Burke et al, 1990 (28) | 43.5 | 28/19 | Tobra 120 mg t.i.d. | Corticosteroids | 7 days | 31/42 | 18/42 |
| Ohkusa et al, 2005 (31) | 39.5 | 12/8 | Amoxi 500 mg t.i.d. + Tetra 500 mg t.i.d. + metro 250 mg t.i.d. | Aminosalicylate + corticosteroids | 14 days | 9/10 | 5/10 |
| Mantzaris et al, 2001 (26) | 41.5 | 26/29 | Cipro 400 mg b.i.d. | 10 days | 23/29 | 20/26 | |
| Mantzaris et al, 1997 (25) | 41.5 | 33/37 | Rifaximin 400 mg b.i.d. | Corticosteroids | 14 days | 24/34 | 26/36 |
| Gionchetti et al, 1999 (29) | Cipro 500–750 mg b.i.d. | 10 days | 9/14 | 5/12 | |||
| Turunen et al, 1998 (30) | 34.2 | 58/25 | Cipro 500–750 mg b.i.d. | Corticosteroids Aminosalicylate | 180 days | 30/38 | 25/45 |
| Ohkusa et al, 2010 (32) | NA | NA | Amoxi 500 mg t.i.d. + tetra 500 mg t.i.d. + metro 250 mg t.i.d. | 90 days | 47/105 | 24/105 | |
| Chapman et al, 1986 (24) | 46.0 | 19/20 | Metro 500 mg t.i.d. i.v. | Prednisone | 5 days | 14/19 | 14/20 |
| Mantzaris et al, 1994 (27) | NA | NA | Metro 0.5 g t.i.d. i.v. + tobra 4 mg/kg t.i.d. | Hydrocortisone | 10 days | 12/19 | 13/20 |
Tobra, tobramycin; amoxi, amoxicillin; tetra, tetracycline; metro, metronidazole; cipro, ciprofloxacin; NA, not available.